<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PONE-D-12-27732</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0052589</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Clinical research design</subject>
            <subj-group>
              <subject>Retrospective studies</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Diagnostic medicine</subject>
            <subj-group>
              <subject>Pathology</subject>
              <subj-group>
                <subject>General pathology</subject>
                <subj-group>
                  <subject>Biomarkers</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Oncology</subject>
            <subj-group>
              <subject>Cancer treatment</subject>
              <subj-group>
                <subject>Chemotherapy and drug treatment</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Cancers and neoplasms</subject>
              <subj-group>
                <subject>Gastrointestinal tumors</subject>
                <subj-group>
                  <subject>Esophageal cancer</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Oncology</subject>
          <subject>Pathology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy</article-title>
        <alt-title alt-title-type="running-head">BRCA1 as a Marker in Esophageal Cancer Treatments</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gao</surname>
            <given-names>Yong</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Zhu</surname>
            <given-names>Jing</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Xiaohui</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Wu</surname>
            <given-names>Qingquan</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Jiang</surname>
            <given-names>Shaoning</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Liu</surname>
            <given-names>Yangqing</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Hu</surname>
            <given-names>Zhibin</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Liu</surname>
            <given-names>Baorui</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Xiaofei</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Department of Medical Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Department of Thoracic Surgery, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Department of Epidemiology and Biostatistics, Nanjing Medical University, Nanjing, China</addr-line>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <addr-line>The Comprehensive Cancer Center, Gulou School of Clinical Medicine, Nanjing Medical University, Nanjing, China</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Samimi</surname>
            <given-names>Goli</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Kinghorn Cancer Centre, Garvan Institute of Medical Research, Australia</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">hayycxf@163.com</email> (XC); <email xlink:type="simple">baoruiliu@hotmail.com</email> (BL)</corresp>
        <fn fn-type="conflict">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: YG BL XC. Performed the experiments: JZ XZ QW. Analyzed the data: SJ YL ZH. Wrote the paper: YG XC.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>1</month>
        <year>2013</year>
      </pub-date>
      <volume>8</volume>
      <issue>1</issue>
      <elocation-id>e52589</elocation-id>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>9</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>11</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Gao et al</copyright-holder>
        <license xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The molecular backgrounds that determine therapeutic effectiveness in esophageal cancer remain largely unknown. Breast cancer susceptibility gene 1 (BRCA1) expression has been found to switch the response to cisplatin- or paclitaxel-based chemotherapy. It remains unclear how variations in BRCA1 expression influence clinical outcomes in esophageal cancer.</p>
        </sec>
        <sec>
          <title>Patients and Methods</title>
          <p>Quantitative real-time polymerase chain reaction (qPCR) was performed to examine BRCA1 mRNA expressions in paraffin-embedded specimens from 144 patients with advanced or metastatic esophageal squamous cell carcinoma who received cisplatin- or docetaxel-based first-line treatments.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Low BRCA1 mRNA expression correlated with increased response rate (RR; <italic>P</italic> = 0.025 and 0.017, respectively) and median overall survival (mOS; <italic>P</italic> = 0.002 and <italic>P</italic>&lt;0.001, respectively) in cisplatin-based chemotherapy or chemoradiotherapy group and also correlated with decreased RR (<italic>P</italic> = 0.017 and 0.024, respectively) and mOS (both <italic>P</italic>&lt;0.001) in docetaxel-based chemotherapy or chemoradiotherapy group. Multivariate analysis revealed that low BRCA1 expression was an independent prognostic factor in cisplatin-based chemotherapy (HR 0.29; 95%CI 0.12–0.71; <italic>P</italic> = 0.007) or chemoradiotherapy (HR 0.12; 95%CI 0.04–0.37; <italic>P</italic>&lt;0.001) group and higher risk for mortality in docetaxel-based chemotherapy (HR 5.02; 95%CI 2.05–12.28; <italic>P</italic>&lt;0.001) or chemoradiotherapy (HR 7.02; 95%CI 2.37–27.77; <italic>P</italic>&lt;0.001) group.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>BRCA1 mRNA expression could be used as a predictive and prognostic marker in esophageal cancer who underwent first-line cisplatin- or docetaxel-based treatments.</p>
        </sec>
      </abstract>
      <funding-group>
        <funding-statement>This work was supported in part by Science Developing Foundation of Nanjing Medical University (09NJMUM063 to Y.G.) and Science Developing Foundation of Huaian Government (HAS2011028 to X.F.C.). The funders had no role in study design, data collection and analysis.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Esophageal cancer, as the sixth most common cause of cancer death in the world, lead to 407,000 deaths estimated in 2008 <xref ref-type="bibr" rid="pone.0052589-Jemal1">[1]</xref>. Patients with such an aggressive tumor have a poor 5-year survival rate less than 20%, which is most likely attributed to the presence of locally advanced and undetected metastatic disease at the time of diagnosis <xref ref-type="bibr" rid="pone.0052589-Shibata1">[2]</xref>. Chemotherapy has been playing important roles in improving survivals of esophageal cancer patients as part of multimodal therapy. Several chemotherapeutic agents commonly used in esophageal cancer have been investigated as single agent therapies with limited response rates as follows: 20% to 26% with cisplatin <xref ref-type="bibr" rid="pone.0052589-Panettiere1">[3]</xref>, 28% to 34% with paclitaxel <xref ref-type="bibr" rid="pone.0052589-Ajani1">[4]</xref> and 15% with 5-fluorouracil <xref ref-type="bibr" rid="pone.0052589-Ezdinli1">[5]</xref>. Combination chemotherapies with these chemotherapeutic agents appeared to be superior to single agent treatment with increased toxicity. Responsiveness to these chemotherapeutic agents and modalities varies among patients owing to genetic variations in pharmacokinetic and pharmacodynamic action <xref ref-type="bibr" rid="pone.0052589-Evans1">[6]</xref>. The molecular backgrounds that determine therapeutic effectiveness in esophageal cancer still remain largely unknown. Some molecular markers have been identified for tailored treatment of esophageal cancer, including platinum related markers [glutathione S-transferase π (GST-π), excision repair cross-complementing 1 (ERCC1) and p-glycoprotein (P-gp)], 5-FU related markers [thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD)] and some proteins in various DNA repair pathways <xref ref-type="bibr" rid="pone.0052589-Alexander1">[7]</xref>–<xref ref-type="bibr" rid="pone.0052589-Joshi1">[9]</xref>. However, these studies mostly focused on the personalized therapies of 5-Fu or/and cisplatin-based treatments.</p>
      <p>Breast cancer susceptibility gene 1 (BRCA1) was firstly identified as one of the genes that conferred genetic predisposition to early-onset breast and ovarian cancer <xref ref-type="bibr" rid="pone.0052589-Kennedy1">[10]</xref>. However, due to its central component involved in multiple aspects of DNA damage responses and pivotal roles in the DNA repair pathway <xref ref-type="bibr" rid="pone.0052589-Kennedy1">[10]</xref>–<xref ref-type="bibr" rid="pone.0052589-Huen1">[13]</xref>, increasing number of experimental and clinical investigations on BRCA1 as a regulator of chemotherapy-induced DNA damage have been performed <xref ref-type="bibr" rid="pone.0052589-Tassone1">[14]</xref>. The vast majority of cellular models have shown that BRCA1 upregulaion is notably associated with DNA repair mediated resistance to the DNA-damaging agent cisplatin through regulation of interstrand cross-link-induced premature senescence <xref ref-type="bibr" rid="pone.0052589-Santarosa1">[15]</xref>, nucleotide excision repair (NER) <xref ref-type="bibr" rid="pone.0052589-Taron1">[16]</xref> and DNA double-strand-break homologous recombination (HR) repair pathway <xref ref-type="bibr" rid="pone.0052589-Yun1">[17]</xref>, <xref ref-type="bibr" rid="pone.0052589-Husain1">[18]</xref>. Conversely, downregulation of BRCA1 confers resistance to antimicrotubule agent taxane through precocious inactivation of the spindle checkpoint <xref ref-type="bibr" rid="pone.0052589-Chabalier1">[19]</xref>, regulation of apoptotic pathways <xref ref-type="bibr" rid="pone.0052589-Mullan1">[20]</xref>, <xref ref-type="bibr" rid="pone.0052589-Quinn1">[21]</xref> and transcriptional modifications of JNK signaling pathway <xref ref-type="bibr" rid="pone.0052589-Lafarge1">[22]</xref>. It was also confirmed in clinic that BRCA1 mutations or alterations in BRCA1 mRNA and protein expression switch the response to cisplatin- or paclitaxel-based chemotherapy as well as influence the survivals in a number of malignancies, including breast cancer <xref ref-type="bibr" rid="pone.0052589-Byrski1">[23]</xref>, <xref ref-type="bibr" rid="pone.0052589-Byrski2">[24]</xref>, ovarian cancer <xref ref-type="bibr" rid="pone.0052589-Weberpals1">[25]</xref>–<xref ref-type="bibr" rid="pone.0052589-Weberpals2">[27]</xref>, gastric cancer <xref ref-type="bibr" rid="pone.0052589-Shim1">[28]</xref>–<xref ref-type="bibr" rid="pone.0052589-Wang1">[30]</xref> and lung cancer <xref ref-type="bibr" rid="pone.0052589-Taron1">[16]</xref>, <xref ref-type="bibr" rid="pone.0052589-Rosell1">[31]</xref>. In our previous studies <xref ref-type="bibr" rid="pone.0052589-Wei1">[29]</xref>, <xref ref-type="bibr" rid="pone.0052589-Wang1">[30]</xref>, high levels of BRCA1 mRNA were negatively associated with cisplatin sensitivity but positively associated with docetaxel sensitivity in gastric cancer patients. Those advanced gastric carcinoma patients with high BRCA1 expression had significantly longer overall survivals compared to those with low expression (25.8 <italic>vs</italic> 9.5 months, <italic>P</italic> = 0.006) who received second-line docetaxel-based chemotherapy after first-line FOLFOX chemotherapy <xref ref-type="bibr" rid="pone.0052589-Wei1">[29]</xref>.</p>
      <p>Cisplatin or docetaxel have been showed the most commonly and effectively utilized chemotherapeutic agents in clinic for patients with esophageal cancer <xref ref-type="bibr" rid="pone.0052589-Leichman1">[32]</xref>–<xref ref-type="bibr" rid="pone.0052589-Muro1">[34]</xref>. However, no studies have addressed how variations in BRCA1 expressions influence clinical outcomes in patients with esophageal cancer treated with these chemotherapeutic agents. In this study, we firstly determined whether the levels of BRCA1 mRNA expression as predictive and prognostic biomarker were associated with clinical outcomes in esophageal cancer patients who received cisplatin- or docetaxel-based treatments.</p>
    </sec>
    <sec id="s2">
      <title>Patients and Methods</title>
      <sec id="s2a">
        <title>Patients</title>
        <p>A total of 155 patients with histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma (stage II-IV) and available paraffin-embedded tumor material for molecular analysis were enrolled in the study. They all had a better Eastern Cooperative Oncology Group performance status (PS; 0 to 2) and had measurable lesions. Among them 79 patients with surgically unresectable or metastatic disease received cisplatin- or docetaxel-based chemotherapy as the first-line treatment. The chemotherapy regimens comprised cisplatin-based regimens (cisplatin 25 mg/m2 on day 1–3 plus 5-fluorouracil 500 mg/m2 on day 1–5), docetaxel-based regimens (docetaxel 60–75 mg/m2 plus 5-fluorouracil 500 mg/m2 on day 1–5) and the combination with both (cisplatin 25 mg/m2 on day 1–3 plus docetaxel 60–75 mg/m2 on day 1). All chemotherapies were repeated every 3–4 weeks for a maximum of six cycles unless there was earlier evidence of disease progression or intolerable adverse effects. The other 76 patients with locally advanced disease received cisplatin or docetaxel-based concurrent chemoradiotherapy (CCRT) or radiotherapy alone as the first-line treatment. CCRT included chemotherapy and concurrent thoracic radiotherapy. The chemotherapy regimens consisted of weekly docetaxel (25 mg/m2 on day 1 per week) plus 5-fluorouracil (300 mg/m2 on day 1–3 per week) or cisplatin (25 mg/m2 on day 1 per week) plus 5-fluorouracil (300 mg/m2 on day 1–3 per week) for 5 weeks. The radiation dose was 50–60 grays (Gy) over 5 weeks (2 Gy/fraction per day, 5 fractions per week) with the use of CT simulation and 3 D treatment planning. Baseline and restaging assessment of measurable lesions were assessed by barium swallow and computed tomography scans, which was repeated every 2 cycle of chemotherapy or 4 weeks after radiotherapy.</p>
        <p>The study was approved by the institutional ethics committee of Huai'an first people's hospital of Nanjing medical university and all patients gave their signed informed consent for the use of the tissue material in translational research.</p>
      </sec>
      <sec id="s2b">
        <title>qPCR analysis for BRCA1 mRNA expression</title>
        <p>We examined BRCA1 gene expression in paraffin-embedded specimens by biopsy under endoscope from the 155 patients as previously described <xref ref-type="bibr" rid="pone.0052589-Wei1">[29]</xref>. Briefly, serial sections of 7-µm thickness with more than 80% tumor cells were prepared from primary tumor blocks by microdissection. Samples were lysed in a proteinase K-containing buffer after paraffin was removed by xylene. RNA was then extracted with phenol-chloroform-isoamyl alcohol followed by precipitation with isopropanol in the presence of glycogen and sodium acetate. RNA was resuspended in water and treated with DNAse I to avoid DNA contamination. cDNA was synthesized by using M-MLV retrotranscriptase enzyme. Template cDNA was amplified with specific primers and probes for BRCA1 and β-actin with using Taqman Universal Master Mix (Applied Biosystems, Foster City, CA). The primer and probe sets as reported in our previous study <xref ref-type="bibr" rid="pone.0052589-Wei1">[29]</xref> were designed using Primer Express 2.0 Software (AB, Foster City, CA, USA). All primers and probes sequence were as follows: β-actin (NM_001101.3) forward <named-content content-type="gene" xlink:type="simple">5′ TGAGCGCGGCTACAGCTT 3′</named-content>, reverse <named-content content-type="gene" xlink:type="simple">5′ TCCTTAATGTCACGCACGATTT 3′</named-content>, and probe 6FAM -<named-content content-type="gene" xlink:type="simple">5′ACCACCA CGGCCGAGCGG 3′</named-content> TAMRA; BRCA1 (NM_007294) forward <named-content content-type="gene" xlink:type="simple">5′GGCTATCCTCTCAGAGTGACATTTTA 3′</named-content>, reverse <named-content content-type="gene" xlink:type="simple">5′GCTTTATCAGGTTATGTTGCATGGT 3′</named-content>, and probe 6FAM -<named-content content-type="gene" xlink:type="simple">5′CCACTCAGCAGAGGG 3′</named-content> MGB.</p>
        <p>Quantitative real-time polymerase chain reaction (qPCR) was performed to quantify gene expression using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems), which is more quantitative and accurate than immunohistochemistry used to assess protein expression as biomarker in clinical studies. The PCR conditions were 50°C for 2 minutes, 95°C for 10 minutes, followed by total 45 cycles at 95°C for 15 seconds and 60°C for 1 minute. Each sample was assayed in triplicate with commercial RNA as positive control and RNase-free water as negative control. In all quantitative experiments, only triplicates with a standard deviation (SD) of the quantification cycle (Cq) values of target genes less than 0.30 were accepted. Quantification of relative gene expression was performed according to the comparative Cq method using β-actin as an endogenous control. Gene expression analyses were conducted with the same calibrators throughout, specifically commercial human lung and liver RNA (Stratagene, La Jolla, CA, USA), to compare gene expression levels between different tumor types and between different cohorts of patients. Final values were determined by the formula 2<sup>−ΔΔCq</sup> [ = 2<sup>−(Cq sample - Cq calibrator)</sup>] <xref ref-type="bibr" rid="pone.0052589-Wei1">[29]</xref>. All analyses were performed at the molecular biology laboratory of Clinical Cancer Institute of Nanjing University (Nanjing, China).</p>
      </sec>
      <sec id="s2c">
        <title>Study design and statistical analysis</title>
        <p>The primary endpoint of the study was to examine the potential effects of BRCA1 mRNA expression levels on clinical responses and overall survival in esophageal cancer patients treated with cisplatin- or docetaxel-based chemotherapy or chemoradiotherapy in the first-line. Clinical responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) <xref ref-type="bibr" rid="pone.0052589-Therasse1">[35]</xref>. Overall survival was calculated from the date of diagnosis to the date of last follow-up or death from any cause. Progression-free survival was not examined because part of patients did not receive further assessments of disease after fist-line treatment and we could not get exact time of progress-free survival of these patients in the present retrospective study. Qualitative variables were summarized by absolute frequencies and percentages and quantitative variables were calculated in median values and ranges. BRCA1 expression values were divided into terciles and cutoff points were calculated according to the median value for the mRNA expression of BRCA1 <xref ref-type="bibr" rid="pone.0052589-Papadaki1">[36]</xref>–<xref ref-type="bibr" rid="pone.0052589-Olaussen1">[38]</xref>. The normality of quantitative variables was analyzed by the Kolmogorov-Smirnov test and compared with the Mann-Whitney U test. All statistical tests were two-sided. In order to correlate gene expression levels with clinical characteristics and compare categorical variables and response percentages, the two-sided chi-square test or Fisher's exact test was used for qualitative variables. The distributions of survival were obtained by the Kaplan-Meier method and compared with the two-sided log-rank test. A multivariate Cox proportional hazards regression model was performed to assess the association between each potential prognostic factor and survival.</p>
        <p>All statistical analyses were performed with a power of 80% and at a 5% level of significance using the Statistical Package for the Social Sciences (SPSS) for Windows version 16 (SPSS Inc, Chicago, IL).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Patients' characteristics</title>
        <p>Clinical data and paraffin-embedded samples from the primary tumors were collected from 155 esophageal squamous cell carcinoma patients treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy in our centre. Successful amplification of BRCA1 gene was achieved in 144 specimens. The median age was 64; 90 patients were male and the majority of patients had PS 0-1. Among them, 72 patients treated with chemotherapy had stage III–IV and other 72 patients treated with chemoradiotherapy or radiotherapy alone had stage II–III at the time of diagnosis. In the chemotherapy group, the overall response rate (RR) was 38.9% and the median overall survival (mOS) was 11.3 months (95% CI, 9.0 to 13.6 months) after a median follow-up period of 10.6 months (range 3.0–30.0); while in the chemoradiotheapy group including those with radiotherapy alone, RR was 72.2% and mOS was 15.0 months (95% CI, 12.4 to 17.6 months) after a median follow-up period of 15.0 months (range 4.0–77.5). Patient characteristics are summarized in <xref ref-type="table" rid="pone-0052589-t001">Table 1</xref>.</p>
        <table-wrap id="pone-0052589-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Patient characteristics of advanced (stage II–IV) esophageal cancer patients.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0052589-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.t001" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">Chemotherapy72</td>
                  <td colspan="3" align="left" rowspan="1">Chemoradiotherapy72</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Characteristic</td>
                  <td align="left" rowspan="1" colspan="1">All patients</td>
                  <td align="left" rowspan="1" colspan="1">Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Cis/Doc</td>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy alone</td>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Doc/5-Fu</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patients, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1">144 (100)</td>
                  <td align="left" rowspan="1" colspan="1">27 (18.8)</td>
                  <td align="left" rowspan="1" colspan="1">29 (20.1)</td>
                  <td align="left" rowspan="1" colspan="1">16 (11.1)</td>
                  <td align="left" rowspan="1" colspan="1">16 (11.1)</td>
                  <td align="left" rowspan="1" colspan="1">29 (20.1)</td>
                  <td align="left" rowspan="1" colspan="1">27 (18.8)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Age, y median (range)</td>
                  <td align="left" rowspan="1" colspan="1">63 (44–79)</td>
                  <td align="left" rowspan="1" colspan="1">60 (51–79)</td>
                  <td align="left" rowspan="1" colspan="1">62 (50–78)</td>
                  <td align="left" rowspan="1" colspan="1">61 (45–70)</td>
                  <td align="left" rowspan="1" colspan="1">69 (44–79)</td>
                  <td align="left" rowspan="1" colspan="1">63 (45–77)</td>
                  <td align="left" rowspan="1" colspan="1">64 (52–78)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Sex, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Male</td>
                  <td align="left" rowspan="1" colspan="1">90 (62.5)</td>
                  <td align="left" rowspan="1" colspan="1">17 (63.0)</td>
                  <td align="left" rowspan="1" colspan="1">16 (55.2)</td>
                  <td align="left" rowspan="1" colspan="1">12 (75.0)</td>
                  <td align="left" rowspan="1" colspan="1">8 (50.0)</td>
                  <td align="left" rowspan="1" colspan="1">19 (65.5)</td>
                  <td align="left" rowspan="1" colspan="1">18 (66.7)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Female</td>
                  <td align="left" rowspan="1" colspan="1">54 (37.5)</td>
                  <td align="left" rowspan="1" colspan="1">10 (37.0)</td>
                  <td align="left" rowspan="1" colspan="1">13 (44.8)</td>
                  <td align="left" rowspan="1" colspan="1">4 (25.0)</td>
                  <td align="left" rowspan="1" colspan="1">8 (50.0)</td>
                  <td align="left" rowspan="1" colspan="1">10 (34.5)</td>
                  <td align="left" rowspan="1" colspan="1">9 (33.3)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">ECOG PS, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">0–1</td>
                  <td align="left" rowspan="1" colspan="1">134 (93.1)</td>
                  <td align="left" rowspan="1" colspan="1">24 (88.9)</td>
                  <td align="left" rowspan="1" colspan="1">26 (89.7)</td>
                  <td align="left" rowspan="1" colspan="1">13 (81.2)</td>
                  <td align="left" rowspan="1" colspan="1">16 (100.0)</td>
                  <td align="left" rowspan="1" colspan="1">28 (96.6)</td>
                  <td align="left" rowspan="1" colspan="1">27 (100.0)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1">10 (6.9)</td>
                  <td align="left" rowspan="1" colspan="1">3 (11.1)</td>
                  <td align="left" rowspan="1" colspan="1">3 (10.3)</td>
                  <td align="left" rowspan="1" colspan="1">3 (18.8)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                  <td align="left" rowspan="1" colspan="1">1 (3.4)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Stage, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">II</td>
                  <td align="left" rowspan="1" colspan="1">31 (21.5)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                  <td align="left" rowspan="1" colspan="1">9 (56.3)</td>
                  <td align="left" rowspan="1" colspan="1">14 (48.3)</td>
                  <td align="left" rowspan="1" colspan="1">8 (29.6)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">III</td>
                  <td align="left" rowspan="1" colspan="1">45 (31.3)</td>
                  <td align="left" rowspan="1" colspan="1">2 (7.4)</td>
                  <td align="left" rowspan="1" colspan="1">1 (3.4)</td>
                  <td align="left" rowspan="1" colspan="1">1 (6.3)</td>
                  <td align="left" rowspan="1" colspan="1">7 (43.7)</td>
                  <td align="left" rowspan="1" colspan="1">15 (51.7)</td>
                  <td align="left" rowspan="1" colspan="1">19 (70.4)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">IV</td>
                  <td align="left" rowspan="1" colspan="1">68 (47.2)</td>
                  <td align="left" rowspan="1" colspan="1">25 (92.6)</td>
                  <td align="left" rowspan="1" colspan="1">28 (96.6)</td>
                  <td align="left" rowspan="1" colspan="1">15 (93.7)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                  <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Site of tumor, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Upper</td>
                  <td align="left" rowspan="1" colspan="1">20 (13.9)</td>
                  <td align="left" rowspan="1" colspan="1">2 (7.4)</td>
                  <td align="left" rowspan="1" colspan="1">3 (10.3)</td>
                  <td align="left" rowspan="1" colspan="1">2 (12.5)</td>
                  <td align="left" rowspan="1" colspan="1">3 (18.8)</td>
                  <td align="left" rowspan="1" colspan="1">6 (20.7)</td>
                  <td align="left" rowspan="1" colspan="1">4 (14.8)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Middle</td>
                  <td align="left" rowspan="1" colspan="1">93 (64.6)</td>
                  <td align="left" rowspan="1" colspan="1">17 (63.0)</td>
                  <td align="left" rowspan="1" colspan="1">17 (58.6)</td>
                  <td align="left" rowspan="1" colspan="1">11 (68.8)</td>
                  <td align="left" rowspan="1" colspan="1">10 (62.5)</td>
                  <td align="left" rowspan="1" colspan="1">20 (70.0)</td>
                  <td align="left" rowspan="1" colspan="1">18 (66.7)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Lower</td>
                  <td align="left" rowspan="1" colspan="1">31 (21.5)</td>
                  <td align="left" rowspan="1" colspan="1">8 (29.6)</td>
                  <td align="left" rowspan="1" colspan="1">9 (31.0)</td>
                  <td align="left" rowspan="1" colspan="1">3 (18.8)</td>
                  <td align="left" rowspan="1" colspan="1">3 (18.8)</td>
                  <td align="left" rowspan="1" colspan="1">3 (10.3)</td>
                  <td align="left" rowspan="1" colspan="1">5 (18.5)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">BRCA1 median (range)</td>
                  <td align="left" rowspan="1" colspan="1">11.96 (0.39–70.03)</td>
                  <td align="left" rowspan="1" colspan="1">10.63 (0.39–70.03)</td>
                  <td align="left" rowspan="1" colspan="1">8.69 (0.56–44.94)</td>
                  <td align="left" rowspan="1" colspan="1">13.58 (4.56–41.93)</td>
                  <td align="left" rowspan="1" colspan="1">10.23 (0.43–44.17)</td>
                  <td align="left" rowspan="1" colspan="1">11.39 (1.16–32.45)</td>
                  <td align="left" rowspan="1" colspan="1">14.37 (2.03–62.90)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Response rate (CR+PR), No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">28 (38.9)</td>
                  <td colspan="3" align="left" rowspan="1">52 (72.2)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Median OS (months, 95% CI)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">11.3 (9.0–13.6)</td>
                  <td colspan="3" align="left" rowspan="1">15.0 (12.4–17.6)</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>BRCA1, breast cancer susceptibility gene 1; Cis, cisplatin; 5-Fu, 5-fluorouracil; Doc, docetaxel; CR, complete response; PR, partial response; OS, overall survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; y, years.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s3b">
        <title>BRCA1 mRNA expression levels</title>
        <p>BRCA1 mRNA expressions were detected successfully in total 144 tumor samples by using quantitative real-time PCR and the median mRNA expression levels of BRCA1 relative to reference gene of β-actin were 11.96 (range 0.39–70.03). Patients were subdivided into two groups based on low (0.39–11.75; mean, 6.60) and high (12.17–70.03; mean, 23.90) levels of BRCA1 mRNA expression using a cutoff value of 11.96. The number of patients with low or high expression levels of BRCA1 was 72 in each cohort. There were no significant correlations between BRCA1 expression levels and clinical characteristics, including age (<italic>P</italic> = 0.317), gender (<italic>P</italic> = 0.388), performance status (<italic>P</italic> = 1.0), stage (<italic>P</italic> = 0.798), grade (<italic>P</italic> = 0.583) or site of tumor (<italic>P</italic> = 0.778) (<xref ref-type="table" rid="pone-0052589-t002">Table 2</xref>).</p>
        <table-wrap id="pone-0052589-t002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Clinical factors associated with BRCA1 mRNA expression levels.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0052589-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.t002" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">BRCA1 expression levels</td>
                  <td colspan="2" align="left" rowspan="1">Overall survival</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Characteristic</td>
                  <td align="left" rowspan="1" colspan="1">low</td>
                  <td align="left" rowspan="1" colspan="1">high</td>
                  <td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
                  <td align="left" rowspan="1" colspan="1">MST (Months, 95% CI)</td>
                  <td align="left" rowspan="1" colspan="1"><italic>P</italic> Log-rank test</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Age, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">≤63</td>
                  <td align="left" rowspan="1" colspan="1">34</td>
                  <td align="left" rowspan="1" colspan="1">40</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">12.0 (10.0–14.0)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">&gt;63</td>
                  <td align="left" rowspan="1" colspan="1">38</td>
                  <td align="left" rowspan="1" colspan="1">32</td>
                  <td align="left" rowspan="1" colspan="1">0.317</td>
                  <td align="left" rowspan="1" colspan="1">14.5 (12.8–16.2)</td>
                  <td align="left" rowspan="1" colspan="1">0.135</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Sex, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Male</td>
                  <td align="left" rowspan="1" colspan="1">48</td>
                  <td align="left" rowspan="1" colspan="1">43</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">12.0 (10.0–14.0)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Female</td>
                  <td align="left" rowspan="1" colspan="1">24</td>
                  <td align="left" rowspan="1" colspan="1">29</td>
                  <td align="left" rowspan="1" colspan="1">0.388</td>
                  <td align="left" rowspan="1" colspan="1">16.0 (13.2–18.8)</td>
                  <td align="left" rowspan="1" colspan="1">0.182</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">ECOG PS, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">0–1</td>
                  <td align="left" rowspan="1" colspan="1">67</td>
                  <td align="left" rowspan="1" colspan="1">67</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">14.0 (12.5–15.5)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1">5</td>
                  <td align="left" rowspan="1" colspan="1">5</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                  <td align="left" rowspan="1" colspan="1">6.1 (5.0–7.2)</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Stage, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">II</td>
                  <td align="left" rowspan="1" colspan="1">15</td>
                  <td align="left" rowspan="1" colspan="1">17</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">16.0 (13.1–18.9)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">III</td>
                  <td align="left" rowspan="1" colspan="1">21</td>
                  <td align="left" rowspan="1" colspan="1">23</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">13.0 (11.1–14.9)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">IV</td>
                  <td align="left" rowspan="1" colspan="1">36</td>
                  <td align="left" rowspan="1" colspan="1">32</td>
                  <td align="left" rowspan="1" colspan="1">0.798</td>
                  <td align="left" rowspan="1" colspan="1">11.3 (9.6–13.0)</td>
                  <td align="left" rowspan="1" colspan="1">0.002</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Grade, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">G1</td>
                  <td align="left" rowspan="1" colspan="1">11</td>
                  <td align="left" rowspan="1" colspan="1">7</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">18.0 (11.1–24.9)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">G2</td>
                  <td align="left" rowspan="1" colspan="1">40</td>
                  <td align="left" rowspan="1" colspan="1">44</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">12.0 (9.8–14.2)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">G3</td>
                  <td align="left" rowspan="1" colspan="1">21</td>
                  <td align="left" rowspan="1" colspan="1">21</td>
                  <td align="left" rowspan="1" colspan="1">0.583</td>
                  <td align="left" rowspan="1" colspan="1">14.0 (11.0–17.0)</td>
                  <td align="left" rowspan="1" colspan="1">0.077</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Site of tumor, No. (%)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Upper</td>
                  <td align="left" rowspan="1" colspan="1">9</td>
                  <td align="left" rowspan="1" colspan="1">11</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">12.8 (6.8–18.8)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Middle</td>
                  <td align="left" rowspan="1" colspan="1">46</td>
                  <td align="left" rowspan="1" colspan="1">47</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">13.5 (11.4–15.6)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Lower</td>
                  <td align="left" rowspan="1" colspan="1">17</td>
                  <td align="left" rowspan="1" colspan="1">14</td>
                  <td align="left" rowspan="1" colspan="1">0.778</td>
                  <td align="left" rowspan="1" colspan="1">13.5 (10.4–16.6)</td>
                  <td align="left" rowspan="1" colspan="1">0.763</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt102">
              <label/>
              <p>BRCA1, breast cancer susceptibility gene 1; CI, confidence interval; MST, median survival time, ECOG, Eastern Cooperative Oncology Group; PS, Performance status;</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>In the whole cohort, 144 esophageal cancer patients had a mOS of 13.0 months (95% CI: 11.5–14.5 months), without statistical significance between the high and low expression of BRCA1 (13.0 <italic>vs</italic> 12.8, <italic>P</italic> = 0.817) (<xref ref-type="fig" rid="pone-0052589-g001">Figure 1</xref>).</p>
        <fig id="pone-0052589-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Median overall survival (mOS) in total 144 advanced and metastasis (stage II–IV) esophageal cancer patients receiving cisplatin- or docetaxel-based first-line treatments according to BRCA1 mRNA levels (for more details see <xref ref-type="table" rid="pone-0052589-t001"><bold>Table 1</bold></xref>).</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.g001" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3c">
        <title>BRCA1 mRNA expression and treatment outcomes in chemotherapy group</title>
        <p>In the chemotherapy group, patients with low BRCA1 expression had increased RR (57.1 <italic>vs</italic> 15.4%, <italic>P</italic> = 0.025) and mOS (15.0 <italic>vs</italic> 7.0, <italic>P</italic> = 0.002; <xref ref-type="fig" rid="pone-0052589-g002">Figure 2A</xref>) compared to those with high expression when treated with cisplatin-based chemotherapy; whereas when treated with docetaxel-based chemotherapy, patients with high BRCA1 mRNA expression had increased RR (69.2 <italic>vs</italic> 25.0%, <italic>P</italic> = 0.017) and mOS (16.0 <italic>vs</italic> 7.0, <italic>P</italic>&lt;0.001; <xref ref-type="fig" rid="pone-0052589-g002">Figure 2B</xref>) compared to those with low expression (<xref ref-type="table" rid="pone-0052589-t003">Table 3</xref>). Then we further investigated correlations of BRCA1 mRNA expression to clinical outcomes in chemotherapy group stratified by BRCA1 levels. Patients with low BRCA1 expression had the best clinical results when treated with cisplatin/5-Fu compared to docetaxel/5-Fu or cisplatin/docetaxel regimens [RR were 57.1, 25.0 (<italic>P</italic> = 0.073) and 28.6% (<italic>P</italic> = 0.217), respectively; mOS were 15.0, 7.0 (<italic>P</italic> = 0.002) and 15.0 months (<italic>P</italic> = 0.450), respectively; <xref ref-type="fig" rid="pone-0052589-g002">Figure 2C</xref>]. For those patients with high BRCA1 expression levels, regimen of docetaxel/5-Fu became the optimization choice in comparison with cisplatin/5-Fu or cisplatin/docetaxel regimens [RR were 69.2, 15.4 (<italic>P</italic> = 0.024) and 33.3% (<italic>P</italic> = 0.096), respectively; mOS were 16.0, 7.0 (<italic>P</italic> = 0.001) and11.8 months (<italic>P</italic> = 0.081), respectively; <xref ref-type="fig" rid="pone-0052589-g002">Figure 2D</xref>] (<xref ref-type="table" rid="pone-0052589-t004">Table 4</xref>).</p>
        <fig id="pone-0052589-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Median overall survival (mOS) in chemotherapy group: mOS in cisplatin/5-Fu (A) and docetaxel/5-Fu (B) subgroup according to BRCA1 mRNA levels (for more details see <xref ref-type="table" rid="pone-0052589-t003"><bold>Table 3</bold></xref>); mOS in low (C) and high (D) BRCA1 mRNA levels according to regimens of chemotherapy (for more details see <xref ref-type="table" rid="pone-0052589-t004"><bold>Table 4</bold></xref>).</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.g002" position="float" xlink:type="simple"/>
        </fig>
        <table-wrap id="pone-0052589-t003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.t003</object-id>
          <label>Table 3</label>
          <caption>
            <title>Outcomes in different treatment groups according to BRCA1 expression levels.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0052589-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.t003" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">RR, <italic>N</italic> (%)</td>
                  <td colspan="3" align="left" rowspan="1">OS (months)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Treatment</td>
                  <td align="left" rowspan="1" colspan="1">BRCA1</td>
                  <td align="left" rowspan="1" colspan="1">CR+PR (%)</td>
                  <td align="left" rowspan="1" colspan="1">SD+PD (%)</td>
                  <td align="left" rowspan="1" colspan="1"><italic>P</italic>-value</td>
                  <td align="left" rowspan="1" colspan="1">No. of patients</td>
                  <td align="left" rowspan="1" colspan="1">Median (95% CI)</td>
                  <td align="left" rowspan="1" colspan="1"><italic>P</italic>-value</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">57.1</td>
                  <td align="left" rowspan="1" colspan="1">42.9</td>
                  <td align="left" rowspan="1" colspan="1">0.025</td>
                  <td align="left" rowspan="1" colspan="1">14</td>
                  <td align="left" rowspan="1" colspan="1">15.0 (10.7–19.3)</td>
                  <td align="left" rowspan="1" colspan="1">0.002</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">15.4</td>
                  <td align="left" rowspan="1" colspan="1">84.6</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">7.0 (5.4–8.6)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">25.0</td>
                  <td align="left" rowspan="1" colspan="1">75.0</td>
                  <td align="left" rowspan="1" colspan="1">0.017</td>
                  <td align="left" rowspan="1" colspan="1">16</td>
                  <td align="left" rowspan="1" colspan="1">7.0 (6.4–7.6)</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">69.2</td>
                  <td align="left" rowspan="1" colspan="1">30.8</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">16.0 (11.7–20.3)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Cis/Doc</td>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">28.6</td>
                  <td align="left" rowspan="1" colspan="1">71.4</td>
                  <td align="left" rowspan="1" colspan="1">0.635</td>
                  <td align="left" rowspan="1" colspan="1">7</td>
                  <td align="left" rowspan="1" colspan="1">15.0 (7.2–22.8)</td>
                  <td align="left" rowspan="1" colspan="1">0.220</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">33.3</td>
                  <td align="left" rowspan="1" colspan="1">66.7</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">9</td>
                  <td align="left" rowspan="1" colspan="1">11.8 (10.1–13.5)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy alone</td>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">72.7</td>
                  <td align="left" rowspan="1" colspan="1">27.3</td>
                  <td align="left" rowspan="1" colspan="1">0.516</td>
                  <td align="left" rowspan="1" colspan="1">11</td>
                  <td align="left" rowspan="1" colspan="1">15.0 (9.2–20.8)</td>
                  <td align="left" rowspan="1" colspan="1">0.839</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">60.0</td>
                  <td align="left" rowspan="1" colspan="1">40.0</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">5</td>
                  <td align="left" rowspan="1" colspan="1">12.5 (2.8–22.2)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">87.5</td>
                  <td align="left" rowspan="1" colspan="1">12.5</td>
                  <td align="left" rowspan="1" colspan="1">0.017</td>
                  <td align="left" rowspan="1" colspan="1">16</td>
                  <td align="left" rowspan="1" colspan="1">24.0 (13.0–35.0)</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">46.2</td>
                  <td align="left" rowspan="1" colspan="1">53.8</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">11.3 (9.1–13.5)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">50.0</td>
                  <td align="left" rowspan="1" colspan="1">50.0</td>
                  <td align="left" rowspan="1" colspan="1">0.024</td>
                  <td align="left" rowspan="1" colspan="1">8</td>
                  <td align="left" rowspan="1" colspan="1">7.5 (6.1–8.9)</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">89.5</td>
                  <td align="left" rowspan="1" colspan="1">10.5</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">19</td>
                  <td align="left" rowspan="1" colspan="1">19.5 (13.9–25.1)</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt103">
              <label/>
              <p>BRCA1, breast cancer susceptibility gene 1; Cis, cisplatin; 5-Fu, 5-fluorouracil; Doc, docetaxel; CR, complete response; PR, partial response; SD, stable disease; PD, progress disease; RR, response rate; OS, overall survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status;</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="pone-0052589-t004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.t004</object-id>
          <label>Table 4</label>
          <caption>
            <title>Outcomes in low or high BRCA1 expression levels according to regimens.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0052589-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.t004" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">RR, N (%)</td>
                  <td colspan="3" align="left" rowspan="1">OS (months)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">BRCA1</td>
                  <td align="left" rowspan="1" colspan="1">Treatment</td>
                  <td align="left" rowspan="1" colspan="1">CR+PR (%)</td>
                  <td align="left" rowspan="1" colspan="1">SD+PD (%)</td>
                  <td align="left" rowspan="1" colspan="1"><italic>P</italic>-value</td>
                  <td align="left" rowspan="1" colspan="1">No. of patients</td>
                  <td align="left" rowspan="1" colspan="1">Median (95% CI)</td>
                  <td align="left" rowspan="1" colspan="1"><italic>P</italic>-value</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">57.1</td>
                  <td align="left" rowspan="1" colspan="1">42.9</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                  <td align="left" rowspan="1" colspan="1">14</td>
                  <td align="left" rowspan="1" colspan="1">15.0 (10.7–19.3)</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">25.0</td>
                  <td align="left" rowspan="1" colspan="1">75.0</td>
                  <td align="left" rowspan="1" colspan="1">0.073</td>
                  <td align="left" rowspan="1" colspan="1">16</td>
                  <td align="left" rowspan="1" colspan="1">7.0 (6.4–7.6)</td>
                  <td align="left" rowspan="1" colspan="1">0.002</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Cis/Doc</td>
                  <td align="left" rowspan="1" colspan="1">28.6</td>
                  <td align="left" rowspan="1" colspan="1">71.4</td>
                  <td align="left" rowspan="1" colspan="1">0.217</td>
                  <td align="left" rowspan="1" colspan="1">7</td>
                  <td align="left" rowspan="1" colspan="1">15.0 (7.2–22.8)</td>
                  <td align="left" rowspan="1" colspan="1">0.450</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">69.2</td>
                  <td align="left" rowspan="1" colspan="1">30.8</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">16.0 (11.7–20.3)</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">15.4</td>
                  <td align="left" rowspan="1" colspan="1">84.6</td>
                  <td align="left" rowspan="1" colspan="1">0.024</td>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">7.0 (5.4–8.6)</td>
                  <td align="left" rowspan="1" colspan="1">0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Cis/Doc</td>
                  <td align="left" rowspan="1" colspan="1">33.3</td>
                  <td align="left" rowspan="1" colspan="1">66.7</td>
                  <td align="left" rowspan="1" colspan="1">0.096</td>
                  <td align="left" rowspan="1" colspan="1">9</td>
                  <td align="left" rowspan="1" colspan="1">11.8 (10.1–13.5)</td>
                  <td align="left" rowspan="1" colspan="1">0.081</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Low</td>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">87.5</td>
                  <td align="left" rowspan="1" colspan="1">12.5</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                  <td align="left" rowspan="1" colspan="1">16</td>
                  <td align="left" rowspan="1" colspan="1">24.0 (13.0–35.0)</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">50.0</td>
                  <td align="left" rowspan="1" colspan="1">50.0</td>
                  <td align="left" rowspan="1" colspan="1">0.046</td>
                  <td align="left" rowspan="1" colspan="1">8</td>
                  <td align="left" rowspan="1" colspan="1">7.5 (6.1–8.9)</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy alone</td>
                  <td align="left" rowspan="1" colspan="1">72.7</td>
                  <td align="left" rowspan="1" colspan="1">27.3</td>
                  <td align="left" rowspan="1" colspan="1">0.332</td>
                  <td align="left" rowspan="1" colspan="1">11</td>
                  <td align="left" rowspan="1" colspan="1">15.0 (9.2–20.8)</td>
                  <td align="left" rowspan="1" colspan="1">0.070</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">High</td>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Doc/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">89.5</td>
                  <td align="left" rowspan="1" colspan="1">10.5</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                  <td align="left" rowspan="1" colspan="1">19</td>
                  <td align="left" rowspan="1" colspan="1">19.5 (13.9–25.1)</td>
                  <td align="left" rowspan="1" colspan="1">1.000</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy+Cis/5-Fu</td>
                  <td align="left" rowspan="1" colspan="1">46.2</td>
                  <td align="left" rowspan="1" colspan="1">53.8</td>
                  <td align="left" rowspan="1" colspan="1">0.007</td>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">11.3 (9.1–13.5)</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Radiotherapy alone</td>
                  <td align="left" rowspan="1" colspan="1">60.0</td>
                  <td align="left" rowspan="1" colspan="1">40.0</td>
                  <td align="left" rowspan="1" colspan="1">0.116</td>
                  <td align="left" rowspan="1" colspan="1">5</td>
                  <td align="left" rowspan="1" colspan="1">12.5 (2.8–22.2)</td>
                  <td align="left" rowspan="1" colspan="1">0.179</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt104">
              <label/>
              <p>BRCA1, breast cancer susceptibility gene 1; Cis, cisplatin; 5-Fu, 5-fluorouracil; Doc, docetaxel; CR, complete response; PR, partial response; SD, stable disease; PD, progress disease; RR, response rate; OS, overall survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status;</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s3d">
        <title>BRCA1 mRNA expression and treatment outcome in chemoradiotherapy group</title>
        <p>No significant differences were observed in RR (72.7 <italic>vs</italic> 60.0%, <italic>P</italic> = 0.516) and mOS (15.0 <italic>vs</italic> 12.0 months, <italic>P</italic> = 0.839; <xref ref-type="fig" rid="pone-0052589-g003">Figure 3A</xref>) between patients with low and high BRCA1 expression who were treated with radiotherapy alone. Nevertheless, when treated with concurrent chemoradiotherapy, patients with low BRCA1 expression had increased RR (87.5 <italic>vs</italic> 46.2%, <italic>P</italic> = 0.017) and mOS (24.0 <italic>vs</italic> 11.3 months, <italic>P</italic>&lt;0.001; <xref ref-type="fig" rid="pone-0052589-g003">Figure 3B</xref>) compared to those with high expressions in the cisplatin-based chemoradiotherapy subgroup; and those with high BRCA1 expression had increased RR (89.5 <italic>vs</italic> 50.0%, <italic>P</italic> = 0.024) and mOS (19.5 <italic>vs</italic> 7.5 months, <italic>P</italic>&lt;0.001; <xref ref-type="fig" rid="pone-0052589-g003">Figure 3C</xref>) compared to those with low expressions in the docetaxel-based chemoradiotherapy subgroup (<xref ref-type="table" rid="pone-0052589-t003">Table 3</xref>). Further study on correlations of BRCA1 expression to clinical outcomes stratified by the BRCA1 expression suggested that cisplatin-based chemoradiotherapy was the best choice of treatment for patients with low BRCA1 expressions compared with treatment of docetaxel-based chemoradiotherapy or radiotherapy alone [RR were 87.5, 50.0 (<italic>P</italic> = 0.046) and 72.7% (<italic>P</italic> = 0.332), respectively; mOS were 24.0, 7.5 (<italic>P</italic>&lt;0.001) and 15.0 months (<italic>P</italic> = 0.070), respectively; <xref ref-type="fig" rid="pone-0052589-g003">Figure 3D</xref>]; whereas, docetaxel-based chemoradiotherapy was the best one for those with high BRCA1 expressions compared with cisplatin-based chemoradiotherapy or radiotherapy alone [RR were 89.5, 46.2 (<italic>P</italic> = 0.007) and 60.0% (<italic>P</italic> = 0.116), respectively; mOS were 19.5, 11.3 (<italic>P</italic>&lt;0.001) and 12.5 months (<italic>P</italic> = 0.179), respectively; <xref ref-type="fig" rid="pone-0052589-g003">Figure 3E</xref>] (<xref ref-type="table" rid="pone-0052589-t004">Table 4</xref>).</p>
        <fig id="pone-0052589-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Median overall survival (mOS) in chemoradiotherapy group: mOS in radiotherapy alone (A), cisplatin-based chemotherapy (B) and docetaxel-based chemotherapy (C) subgroup according to BRCA1 mRNA levels (for more details see <xref ref-type="table" rid="pone-0052589-t003"><bold>Table 3</bold></xref>); mOS in low (D) and high (E) BRCA1 mRNA levels according to regimens of chemoradiotherapy (for more details see <xref ref-type="table" rid="pone-0052589-t004"><bold>Table 4</bold></xref>).</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.g003" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>Univariate and multivariate analyses</title>
        <p>Univariate analysis demonstrated that a significant association was observed between mOS and PS (<italic>P</italic>&lt;0.001) or stage of disease (<italic>P</italic> = 0.002) in the whole cohort. No other association between clinical characteristics and survival was found (<xref ref-type="table" rid="pone-0052589-t002">Table 2</xref>).</p>
        <p>Cox proportional hazard analysis revealed that low BRCA1 expression as an independent prognostic factor was significant associated with increased mOS in cisplatin-based chemotherapy (HR 0.29; 95%CI 0.12–0.71; <italic>P</italic> = 0.007) or chemoradiotherapy (HR 0.12; 95%CI 0.04–0.37; <italic>P</italic>&lt;0.001) group, whereas low BRCA1 expression emerged conversely as higher risk for mortality associated with decreased mOS in docetaxel-based chemotherapy ( HR 5.02; 95%CI 2.05–12.28; <italic>P</italic>&lt;0.001) or chemoradiotherapy (HR 7.02; 95%CI 2.37–27.77; <italic>P</italic>&lt;0.001) group (<xref ref-type="table" rid="pone-0052589-t005">Table 5</xref>).</p>
        <table-wrap id="pone-0052589-t005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052589.t005</object-id>
          <label>Table 5</label>
          <caption>
            <title>Multivariate analysis of factors associated with overall survival of esophageal cancer according to regimens.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0052589-t005-5" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052589.t005" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="3" align="left" rowspan="1">Cis/5-Fu</td>
                  <td colspan="3" align="left" rowspan="1">Doc/5-Fu</td>
                  <td colspan="3" align="left" rowspan="1">Radiotherapy+Cis/5-Fu</td>
                  <td colspan="3" align="left" rowspan="1">Radiotherapy+Doc/5-Fu</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">HR.</td>
                  <td align="left" rowspan="1" colspan="1">CI,</td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>P</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">HR.</td>
                  <td align="left" rowspan="1" colspan="1">CI,</td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>P</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">HR.</td>
                  <td align="left" rowspan="1" colspan="1">CI</td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>P</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">HR.</td>
                  <td align="left" rowspan="1" colspan="1">CI,</td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>P</italic>
                  </td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">BRCA1 (low <italic>vs</italic> high)</td>
                  <td align="left" rowspan="1" colspan="1">0.29</td>
                  <td align="left" rowspan="1" colspan="1">0.12–0.71</td>
                  <td align="left" rowspan="1" colspan="1">0.007</td>
                  <td align="left" rowspan="1" colspan="1">5.02</td>
                  <td align="left" rowspan="1" colspan="1">2.05–12.28</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">0.04–0.37</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                  <td align="left" rowspan="1" colspan="1">7.02</td>
                  <td align="left" rowspan="1" colspan="1">2.37–27.77</td>
                  <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Stage (II vs III or III vs IV)</td>
                  <td align="left" rowspan="1" colspan="1">0.23</td>
                  <td align="left" rowspan="1" colspan="1">0.03–1.76</td>
                  <td align="left" rowspan="1" colspan="1">0.156</td>
                  <td align="left" rowspan="1" colspan="1">4.39</td>
                  <td align="left" rowspan="1" colspan="1">0.51–38.03</td>
                  <td align="left" rowspan="1" colspan="1">0.179</td>
                  <td align="left" rowspan="1" colspan="1">1.72</td>
                  <td align="left" rowspan="1" colspan="1">0.71–4.18</td>
                  <td align="left" rowspan="1" colspan="1">0.232</td>
                  <td align="left" rowspan="1" colspan="1">1.14</td>
                  <td align="left" rowspan="1" colspan="1">0.37–3.45</td>
                  <td align="left" rowspan="1" colspan="1">0.823</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">PS (0–1 <italic>vs</italic> 2)</td>
                  <td align="left" rowspan="1" colspan="1">0.33</td>
                  <td align="left" rowspan="1" colspan="1">0.08–1.37</td>
                  <td align="left" rowspan="1" colspan="1">0.127</td>
                  <td align="left" rowspan="1" colspan="1">0.13</td>
                  <td align="left" rowspan="1" colspan="1">0.03–0.54</td>
                  <td align="left" rowspan="1" colspan="1">0.005</td>
                  <td align="left" rowspan="1" colspan="1">0.47</td>
                  <td align="left" rowspan="1" colspan="1">0.004–0.51</td>
                  <td align="left" rowspan="1" colspan="1">0.012</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt105">
              <label/>
              <p>BRCA1, breast cancer susceptibility gene 1; HR, hazard ratio; CI, confidence interval; <italic>P, P</italic>-value.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>In present study, we firstly applied qPCR analysis of BRCA1 mRNA expression in formalin-fixed paraffin-embedded tumor tissue in advanced and metastasis esophageal cancer and evaluated the relationship between BRCA1 mRNA expression levels and cisplatin- or docetaxel-based treatments. The antimetabolite 5-fluorouracil was used as combination agent in cisplatin- or docetaxel-based treatment because BRCA1 failed to modulate resistance or sensitivity to it <xref ref-type="bibr" rid="pone.0052589-Quinn1">[21]</xref>. BRCA1 was discovered to be involved in the inverse resistance relationship between cisplatin- and docetaxel-based treatments in esophageal cancer patients. Over expression of BRCA1 mRNA was negatively associated with RR and mOS in patients treated with cisplatin-based chemotherapy or chemoradiotherapy; whereas conversely, over expression of BRCA1 was positively associated with clinical outcomes in those patients who received docetaxel-based treatments. Multivariate analysis revealed that low BRCA1 expression was an independent prognostic factor for patients with cisplatin-based treatment and conversely higher risk for mortality for patients with docetaxel-based treatment. These findings support the hypothesis that BRCA1 mRNA expression levels could be a valid indicator of differential sensitivity to cisplatin or docetaxel in esophageal cancer, which is consistent with findings in previous clinical studies on other malignancies <xref ref-type="bibr" rid="pone.0052589-Byrski1">[23]</xref>–<xref ref-type="bibr" rid="pone.0052589-Rosell1">[31]</xref>. As a predictive marker in previous studies, overexpression of BRCA1 was significantly correlated with higher RR and progression-free survival (PFS) but not with mOS in non-small-cell lung cancer (NSCLC) treated with docetaxel-gemcitabine as first-line chemotherapy <xref ref-type="bibr" rid="pone.0052589-Papadaki1">[36]</xref>; BRCA1 mutation appeared to be related with high pathologic complete response in breast cancer treated with platinum-based neoadjuvant therapy <xref ref-type="bibr" rid="pone.0052589-Byrski1">[23]</xref>, <xref ref-type="bibr" rid="pone.0052589-Byrski2">[24]</xref>. Meanwhile, as a prognostic marker, low BRCA1 expression correlated with improved survival in advanced ovarian cancer who received platinum-based chemotherapy <xref ref-type="bibr" rid="pone.0052589-Weberpals2">[27]</xref> and high BRCA1 expression correlated with longer mOS in gastric cancer patients treated with second-line docetaxel-based chemotherapy after first-line FOLFOX chemotherapy <xref ref-type="bibr" rid="pone.0052589-Wei1">[29]</xref>. As both predictive and prognostic marker, low BRCA1 protein expression correlated with better clinical outcome in terms of both PFS and OS in patients with epithelial ovarian cancer treated with platinum <xref ref-type="bibr" rid="pone.0052589-Weberpals1">[25]</xref>, <xref ref-type="bibr" rid="pone.0052589-Carser1">[26]</xref>. In the present study, BRCA1 mRNA determined by qPCR with merits of better quantitative and accurate measurement compared to protein expression determined by immunohistochemistry, was found to be both predictive marker associated with RR and prognostic marker associated with mOS in esophageal cancer patients treated with docetaxel- or cisplatin-based treatments.</p>
      <p>These results are also in line with findings in the pre-clinical cell line model, which indicated that reconstitution of wild-type BRCA1 function into human breast cancer HCC1937 cell line caused a 1000-fold increase in sensitivity to taxane and a 20-fold increase in resistance to cisplatin <xref ref-type="bibr" rid="pone.0052589-Quinn1">[21]</xref>. Several mechanisms were involved in the resistance of DNA-damaging agent cisplatin <xref ref-type="bibr" rid="pone.0052589-Santarosa1">[15]</xref>–<xref ref-type="bibr" rid="pone.0052589-Husain1">[18]</xref> as mentioned previously. Among them, NER is considered as the main mechanism for the resistance of cisplatin through removal of the cisplatin-DNA adducts that mainly cause cellular death and tumor response <xref ref-type="bibr" rid="pone.0052589-Olaussen1">[38]</xref>. ERCC1 involved in GG-NER pathway has been proved an effective predictive marker of cisplatin response <xref ref-type="bibr" rid="pone.0052589-Furuta1">[39]</xref>. By contrast, BRCA1 may be a better predictive marker of cisplatin response owing to its involvement in TC-NER that is relevant for the antiproliferative activity of cisplatin <xref ref-type="bibr" rid="pone.0052589-Taron1">[16]</xref>. Meanwhile, downregulation of BRCA1 confers resistance to taxane through inactivation of the spindle checkpoint, regulation of apoptotic and JNK signaling pathways <xref ref-type="bibr" rid="pone.0052589-Chabalier1">[19]</xref>–<xref ref-type="bibr" rid="pone.0052589-Lafarge1">[22]</xref>.</p>
      <p>Cisplatin- and docetaxel-based treatments were found to be the optimized choices for patients with low and high expression of BRCA1 to get more clinical benefits in the present study, respectively. Survival benefits can be brought to esophageal caner patients by appropriate treatments based on BRCA1 expression. In this retrospective study, patients with stage III–IV had longer mOS of 15.0 months (95% CI: 10.7–19.3) when treated with cisplatin-based chemotherapy for low BRCA1 expression and 16.0 months (95% CI: 11.7–20.3) when treated with docetaxel-based chemotherapy for high BRCA1 expression. By contrast, previous phase II clinical trial indicated that esophageal cancer patients with similar stages only had mOS of 10.8 months when treated with a combination therapy of three chemotherapeutic agents including paclitaxel, cisplatin and 5-FU <xref ref-type="bibr" rid="pone.0052589-Ilson1">[33]</xref>. Meanwhile, no clinical benefits were observed in patients with low BRCA1 expression who received docetaxel-based treatments and patients with high BRCA1 expression who received cisplatin-based treatments (<xref ref-type="table" rid="pone-0052589-t004">Table 4</xref>). Patients with low BRCA1 expression treated with cisplatin/docetaxel chemotherapy had similar OS (15.0 <italic>vs</italic> 15.0 months, <italic>P</italic> = 0.450, <xref ref-type="fig" rid="pone-0052589-g002">Figure 2C</xref>) compared to cispalin/5-Fu chemotherapy and patients with high BRCA1 expression treated with cisplatin/docetaxel chemotherapy also had no better OS (11.8 vs 16.0 months, P = 0.081, <xref ref-type="fig" rid="pone-0052589-g002">Figure 2D</xref>) compared to docetaxel/5-Fu chemotherapy (<xref ref-type="table" rid="pone-0052589-t004">Table 4</xref>). These results were consistent with findings in previous study on NSCLC that overexpression of BRCA1 was significantly correlated with better clinical outcomes in patients treated with docetaxel/gemcitabine but not in those treated with cisplatin/docetaxel regimen <xref ref-type="bibr" rid="pone.0052589-Papadaki1">[36]</xref>.</p>
      <p>Radiotherapy is considered extremely effective in local control of cancer, but its curative potential is often limited by intrinsic radioresistance of the tumor cells. BRCA1 is involved in HR repair of double strands break with relation to radiation resistance and considered important in maintenance of genomic stability through DNA repair while cell DNA-damage takes place due to radiation <xref ref-type="bibr" rid="pone.0052589-Yun1">[17]</xref>, which is supported by the observation that cells deficient in BRCA1 are highly sensitive to radiation <xref ref-type="bibr" rid="pone.0052589-Shen1">[40]</xref>. Nevertheless, we didn't observe the effect of BRCA1 on resistance of radiotherapy for patients with esophageal cancer. In present study, there was no significant difference in clinical outcomes between patients with low and high BRCA1 expression when treated with radiotherapy alone. This result was in agreement to the previous study of breast cancer, which showed no evidence of increased radiation sensitivity in breast tissue heterozygous for a BRCA1/2 germline mutation <xref ref-type="bibr" rid="pone.0052589-Byrski1">[23]</xref>. This finding might also explain why BRCA1 mRNA expression was significantly associated to cisplatin- or docetaxel-based concurrent chemoradiotherapy in the same trend that existed in chemotherapy group.</p>
      <p>Several limitations exist in this study which is based on an unplanned and retrospective analysis, lack of validation group and has relatively small number of patients in treatment subgroups. However, we provide the first evidence to support the tumor mRNA expression levels of BRCA1 as predictive and prognostic marker in esophageal cancer with cisplatin- or docetaxel-based treatments and indicated the need to further validate in a large number of patients prospectively.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful for the assistance of L. X. Yu and J Wei in facilitating this project.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0052589-Jemal1">
        <label>1</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bray</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Center</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Global cancer statistics</article-title>. <source>CA Cancer J Clin</source> <volume>61</volume>: <fpage>69</fpage>–<lpage>90</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Shibata1">
        <label>2</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kokubu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Saito</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Narisawa-Saito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sasaki</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer</article-title>. <source>Neoplasia</source> <volume>13</volume>: <fpage>864</fpage>–<lpage>873</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Panettiere1">
        <label>3</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Panettiere</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Leichman</surname><given-names>LP</given-names></name>, <name name-style="western"><surname>Tilchen</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>TT</given-names></name> (<year>1984</year>) <article-title>Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study</article-title>. <source>Cancer Treat Rep</source> <volume>68</volume>: <fpage>1023</fpage>–<lpage>1024</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Ajani1">
        <label>4</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Ilson</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Daugherty</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pazdur</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>PM</given-names></name>, <etal>et al</etal>. (<year>1994</year>) <article-title>Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus</article-title>. <source>J Natl Cancer Inst</source> <volume>86</volume>: <fpage>1086</fpage>–<lpage>1091</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Ezdinli1">
        <label>5</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ezdinli</surname><given-names>EZ</given-names></name>, <name name-style="western"><surname>Gelber</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Desai</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Falkson</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Moertel</surname><given-names>CG</given-names></name>, <etal>et al</etal>. (<year>1980</year>) <article-title>Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience</article-title>. <source>Cancer</source> <volume>46</volume>: <fpage>2149</fpage>–<lpage>2153</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Evans1">
        <label>6</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name> (<year>1999</year>) <article-title>Pharmacogenomics: translating functional genomics into rational therapeutics</article-title>. <source>Science</source> <volume>286</volume>: <fpage>487</fpage>–<lpage>491</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Alexander1">
        <label>7</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alexander</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>XZ</given-names></name>, <name name-style="western"><surname>Niemierko</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Mak</surname><given-names>RH</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source> <volume>83</volume>: <fpage>164</fpage>–<lpage>171</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Harpole1">
        <label>8</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harpole</surname><given-names>DH</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Moore</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name>, <name name-style="western"><surname>Aloia</surname><given-names>T</given-names></name>, <name name-style="western"><surname>D'Amico</surname><given-names>TA</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer</article-title>. <source>Clin Cancer Res</source> <volume>7</volume>: <fpage>562</fpage>–<lpage>569</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Joshi1">
        <label>9</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Joshi</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Shirota</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Danenberg</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Conlon</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Salonga</surname><given-names>DS</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer</article-title>. <source>Clin Cancer Res</source> <volume>11</volume>: <fpage>2215</fpage>–<lpage>2221</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Kennedy1">
        <label>10</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kennedy</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Harkin</surname><given-names>DP</given-names></name> (<year>2002</year>) <article-title>BRCA1: mechanisms of inactivation and implications for management of patients</article-title>. <source>Lancet</source> <volume>360</volume>: <fpage>1007</fpage>–<lpage>1014</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Roy1">
        <label>11</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roy</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Powell</surname><given-names>SN</given-names></name> (<year>2012</year>) <article-title>BRCA1 and BRCA2: different roles in a common pathway of genome protection</article-title>. <source>Nat Rev Cancer</source> <volume>12</volume>: <fpage>68</fpage>–<lpage>78</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Matsuoka1">
        <label>12</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matsuoka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ballif</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Smogorzewska</surname><given-names>A</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>ER</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Hurov</surname><given-names>KE</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage</article-title>. <source>Science</source> <volume>316</volume>: <fpage>1160</fpage>–<lpage>1166</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Huen1">
        <label>13</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huen</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Sy</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>BRCA1 and its toolbox for the maintenance of genome integrity</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>11</volume>: <fpage>138</fpage>–<lpage>148</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Tassone1">
        <label>14</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tassone</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tagliaferri</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Perricelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Blotta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Quaresima</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells</article-title>. <source>Br J Cancer</source> <volume>88</volume>: <fpage>1285</fpage>–<lpage>1291</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Santarosa1">
        <label>15</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santarosa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Del</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Tonin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Caragnano</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Viel</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers</article-title>. <source>Mol Cancer Ther</source> <volume>8</volume>: <fpage>844</fpage>–<lpage>854</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Taron1">
        <label>16</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taron</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rosell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Felip</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mendez</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Souglakos</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer</article-title>. <source>Hum Mol Genet</source> <volume>13</volume>: <fpage>2443</fpage>–<lpage>2449</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Yun1">
        <label>17</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yun</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Hiom</surname><given-names>K</given-names></name> (<year>2009</year>) <article-title>CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle</article-title>. <source>Nature</source> <volume>459</volume>: <fpage>460</fpage>–<lpage>463</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Husain1">
        <label>18</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Husain</surname><given-names>A</given-names></name>, <name name-style="western"><surname>He</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Venkatraman</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Spriggs</surname><given-names>DR</given-names></name> (<year>1998</year>) <article-title>BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II)</article-title>. <source>Cancer Res</source> <volume>58</volume>: <fpage>1120</fpage>–<lpage>1123</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Chabalier1">
        <label>19</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chabalier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lamare</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Racca</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Privat</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Valette</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance</article-title>. <source>Cell Cycle</source> <volume>5</volume>: <fpage>1001</fpage>–<lpage>1007</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Mullan1">
        <label>20</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mullan</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Gilmore</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>McWilliams</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents</article-title>. <source>Oncogene</source> <volume>20</volume>: <fpage>6123</fpage>–<lpage>6131</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Quinn1">
        <label>21</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Quinn</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Mullan</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Gilmore</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Carty</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis</article-title>. <source>Cancer Res</source> <volume>63</volume>: <fpage>6221</fpage>–<lpage>6228</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Lafarge1">
        <label>22</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lafarge</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sylvain</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ferrara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bignon</surname><given-names>YJ</given-names></name> (<year>2001</year>) <article-title>Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway</article-title>. <source>Oncogene</source> <volume>20</volume>: <fpage>6597</fpage>–<lpage>6606</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Byrski1">
        <label>23</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Byrski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gronwald</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huzarski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Grzybowska</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Budryk</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy</article-title>. <source>J Clin Oncol</source> <volume>28</volume>: <fpage>375</fpage>–<lpage>379</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Byrski2">
        <label>24</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Byrski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Huzarski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dent</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gronwald</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zuziak</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source> <volume>115</volume>: <fpage>359</fpage>–<lpage>363</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Weberpals1">
        <label>25</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weberpals</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Squire</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Amin</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study</article-title>. <source>Ann Oncol</source> <volume>22</volume>: <fpage>2403</fpage>–<lpage>2410</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Carser1">
        <label>26</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carser</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Michie</surname><given-names>CO</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>McCluggage</surname><given-names>WG</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer</article-title>. <source>Gynecol Oncol</source> <volume>123</volume>: <fpage>492</fpage>–<lpage>498</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Weberpals2">
        <label>27</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weberpals</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Garbuio</surname><given-names>K</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Clark-Knowles</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Doucette</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer</article-title>. <source>Int J Cancer</source> <volume>124</volume>: <fpage>806</fpage>–<lpage>815</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Shim1">
        <label>28</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shim</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Yun</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>WK</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>SH</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin</article-title>. <source>Cancer Sci</source> <volume>101</volume>: <fpage>1247</fpage>–<lpage>1254</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Wei1">
        <label>29</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer</article-title>. <source>J Natl Cancer Inst</source> <volume>103</volume>: <fpage>1552</fpage>–<lpage>1556</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Wang1">
        <label>30</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel</article-title>. <source>BMC Cancer</source> <volume>8</volume>: <fpage>97</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Rosell1">
        <label>31</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Perez-Roca</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Cobo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Moran</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression</article-title>. <source>PLoS One</source> <volume>4</volume>: <fpage>e5133</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Leichman1">
        <label>32</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leichman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>BT</given-names></name> (<year>1991</year>) <article-title>Experience with cisplatin in treatment regimens for esophageal cancer</article-title>. <source>Semin Oncol</source> <volume>18</volume>: <fpage>64</fpage>–<lpage>72</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Ilson1">
        <label>33</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ilson</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Ajani</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bhalla</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Forastiere</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus</article-title>. <source>J Clin Oncol</source> <volume>16</volume>: <fpage>1826</fpage>–<lpage>1834</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Muro1">
        <label>34</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muro</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hamaguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ohtsu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boku</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer</article-title>. <source>Ann Oncol</source> <volume>15</volume>: <fpage>955</fpage>–<lpage>959</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Therasse1">
        <label>35</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Therasse</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Arbuck</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Eisenhauer</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Wanders</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>RS</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title>. <source>J Natl Cancer Inst</source> <volume>92</volume>: <fpage>205</fpage>–<lpage>216</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Papadaki1">
        <label>36</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Papadaki</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tsaroucha</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kaklamanis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lagoudaki</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Trypaki</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer</article-title>. <source>Br J Cancer</source> <volume>104</volume>: <fpage>316</fpage>–<lpage>323</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Rosell2">
        <label>37</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Scagliotti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Danenberg</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Lord</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Bepler</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer</article-title>. <source>Oncogene</source> <volume>22</volume>: <fpage>3548</fpage>–<lpage>3553</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Olaussen1">
        <label>38</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Olaussen</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Dunant</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fouret</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Brambilla</surname><given-names>E</given-names></name>, <name name-style="western"><surname>André</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy</article-title>. <source>N Engl J Med</source> <volume>355</volume>: <fpage>983</fpage>–<lpage>991</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Furuta1">
        <label>39</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Furuta</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ueda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Aune</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sarasin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kraemer</surname><given-names>KH</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells</article-title>. <source>Cancer Res</source> <volume>62</volume>: <fpage>4899</fpage>–<lpage>4902</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052589-Shen1">
        <label>40</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname><given-names>SX</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Weinstein</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability</article-title>. <source>Oncogene</source> <volume>17</volume>: <fpage>3115</fpage>–<lpage>3124</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>